Abstract-Interleukin-11 was developed to reduce chemotherapyinduced thrombocytopenia; however, its clinical use was limited by severe adverse effects in humans. PEGylated interleukin-11 (BBT-059), developed by Bolder Biotechnology, Inc., exhibited a longer half-life in rodents and induced longer-lasting increases in hematopoietic cells than interleukin-11. A single dose of 1.2 mg kg −1 of BBT-059, administered subcutaneously to CD2F1 mice (12-14 wk, male) was found to be safe in a 14 d toxicity study. The drug demonstrated its efficacy both as a prophylactic countermeasure and a mitigator in CD2F1 mice exposed to , administered either 24 h pre-, 4 h post-, or 24 h postirradiation increased the survival of mice to 70-100% from lethal doses of radiation. Preadministration (−24 h) of the drug conferred a significantly (p < 0.05) higher survival compared to 24 h post-total-body irradiation. There was significantly accelerated recovery from radiation-induced peripheral blood neutropenia and thrombocytopenia in animals pretreated with BBT-059. The drug also increased bone marrow cellularity and megakaryocytes and accelerated multilineage hematopoietic recovery. In addition, BBT-059 inhibited the induction of radiation-induced hematopoietic biomarkers, thrombopoietin, erythropoietin, and Flt-3 ligand. These results indicate that BBT-059 is a promising radiation countermeasure, demonstrating its potential to be used both pre-and postirradiation for hematopoietic acute radiation syndrome with a broad window for medical management in a radiological or nuclear event. Health Phys. 115(1): 65-76; 2018 
INTRODUCTION
BECAUSE OF the growing threat of global nuclear or radiological terrorism, development of prophylactic, mitigatory, and therapeutic measures against radiation injury is a national priority (Singh et al. 2014 ). In the case of an unintentional or deliberate acute radiation exposure, medical care would focus primarily on giving prophylactic countermeasures to the first responders and uniformed personnel before deployment to the radiation-exposed field for rescue missions (Singh et al. 2014) . Radiation prophylactic agents are also useful for civilians expected to be exposed to radiation fallout fields during evacuation procedures (Singh et al. 2014) . Mitigators are needed to protect first responders as well as civilians exposed to acute radiation, and therapeutics are needed for treatment after symptoms develop, mainly due to late-arising injuries (Singh et al. 2014) . Although many medical countermeasures for acute radiation syndrome (ARS; Barshishat-Kupper et al. 2011) are in different stages of development (Ghosh et al. 2009a and b; Singh et al. 2014) , only granulocyte colony-stimulating factor (G-CSF) (filgrastim, Neupogen) and PEGylated G-CSF (pegfilgrastim, Neulasta) have been approved for hematopoietic ARS (H-ARS) by the U.S. Food and Drug Administration (FDA) and they are in the strategic national stockpile (SNS); however, filgrastim requires multiple administrations until recovery of neutrophils (USFDA 2015a and b) . Therefore, agents that demonstrate a broad window of efficacy are very important for the development of medical management after a radiological/nuclear event.
Interleukin-11 (IL-11; 20 kDa) is a multifunctional cytokine of the interleukin-6 family with anti-inflammatory and hematopoietic proliferative properties, being a key regulator of megakaryocyte maturation (Hauer-Jensen 2014) . In addition to hematopoietic protection, a cytoprotective role of IL-11 to protect intestinal crypt cells was also documented, and recombinant human IL-11 was used for the treatment of inflammatory bowel disease (Potten 1995 (Potten , 1996 . Systemic administration of IL-11 in mice was found to reduce intestinal mucosal injury and protect crypt 1 Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, 8901 Wisconsin Av., Bethesda, MD 20889;  cells after exposure to total-body radiation (TBI). Although recombinant human IL-11 was developed and marketed to reduce chemotherapy-induced thrombocytopenia, its clinical use is limited by the requirement of multiple daily injections and severe adverse effects in humans, including significant fluid retention and multiorgan failure. IL-11 was found to be effective both as a prophylactic countermeasure and as a mitigator after TBI in rodent models (Potten 1995; Burnett et al. 2013) . To reduce toxicity and increase efficacy, the authors developed PEGylated IL-11 (BBT-059; Bolder Biotechnology, Inc., 2425 55th St., Suite 210, Boulder, CO 80301 USA), which demonstrated a longer half-life in plasma in rodents and increased the induction period of hematopoietic stem cells compared to IL-11 (Lee et al. 2012; Plett et al. 2014) . A single dose of BBT-059 in rats stimulated circulating platelets that lasted up to 10 d (Lee et al. 2012) .
In an earlier study by Plett et al. (2014) , a single dose of BBT-059 was found to increase survival and to increase white blood cells, platelets, lymphocytes, and neutrophils in C57BL/6 mice exposed to lethal doses of TBI resulting in 50% mortality in 30 d (LD50/30) or 70% mortality in 30 d (LD70/30). Genetic variations in humans may contribute to the considerable difference in the extent and rate of loss of cells after TBI, resulting in radiation-induced lymphocyte apoptosis (Kusunoki and Hayashi 2008; Schnarr et al. 2007 ). Previous studies reported that inherent variation in mouse strains causes changes in radiosensitivity, resulting in differences in survival after TBI (Williams et al. 2010) . This is mainly due to changes in bacterial populations, which stimulate innate immune responses differentially. These results suggested that radioprotectors and mitigators of the immune system should be tested in more than one strain of mouse to ensure its effectiveness in all populations irrespective of genetic variations (Williams et al. 2010) . In this study, it was demonstrated, for the first time, that BBT-059 is effective as a radiation countermeasure given 24 h pre-TBI as well as 4 h post-TBI. The efficacy of BBT-059 in the CD2F1 mouse strain when administered 24 h post-TBI was also validated. In addition, it was shown that BBT-059, administered 24 h pre-TBI, accelerated recovery from radiation-induced peripheral blood cytopenia, accelerated restoration of sternal bone marrow, and protected bone marrow progenitor cells, as well as attenuated protein biomarkers of H-ARS.
MATERIALS AND METHODS

Mice
Twelve-to fourteen-week-old CD2F1 male mice used in these studies were purchased from Envigo (8520 Allison Pointe Blvd., #400, Indianapolis, IN 46250 USA). The mice were housed in the Armed Forces Radiobiology Research Institute's (AFRRI) vivarium accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. The animals received Harlan Teklad Rodent Diet 8604 (Envigo) and acidified water (pH 2.5-3.0) ad libitum, were housed under 12 h light/dark cycles, and were acclimatized for two weeks before the start of each study. All procedures in these studies were performed under an approved protocol by the Department of Defense Institutional Animal Care Use Committee (IACUC).
Drug preparation
BBT-059 is a long-acting PEGylated IL-11 analog created using site-specific PEGylation technology and is modified with a single-branched, 40 kDa polyethylene glycol (PEG) at a cysteine residue (PEG-*179C) added to the C-terminus of the protein (Lee et al. 2012) . In these studies, BBT-059 was prepared in formulation buffer (10 mM sodium phosphate, 4% mannitol, 1% sucrose, pH 6.2) at the specific doses used in studies. Formulation buffer and saline (0.9%) were used as controls. Drug and controls were injected as a single dose (0.1 mL) subcutaneously (SC) at the nape of the neck.
Irradiation
The experimental animals received a single exposure of 60
Co gamma TBI at an estimated dose rate of 0.6 Gy min −1 in the AFRRI radiation facility. The mice were placed in ventilated Lucite ™ boxes arranged in an array using plastic racks during the exposure. The alanine electron spin resonance (ESR) dosimetry system (ASTM 1996) was used to measure dose rates to water in cores of acrylic mouse phantoms as described earlier (Ghosh et al. 2009a ). The radiation field was uniform within ± 2%.
Fourteen-day acute toxicity study
To determine the safety of BBT-059 in CD2F1 mice, a 14 d toxicity study was conducted (Swift et al. 2014) . Two groups of CD2F1 male mice (n = 6 per group) were subcutaneously administered either BBT-059 (1.2 mg kg −1 ) or its vehicle formulation buffer. The animals were monitored for acute (1 to 4 h) signs of toxicity after administration of the drug, then daily for 14 d. Signs of acute toxicity included decreased activity, squinting eyes, hunching, labored breathing, or mortality. Weights of the animals were recorded at various intervals during the study. All animals were euthanized on day 14, and a gross necropsy was carried out for any abnormal pathology in all major organs.
Survival studies
The initial survival studies consisted of testing one drug dose of BBT-059 (0.3 mg kg −1 ), one route of administration (SC), three drug regimens (one pre-and two post-TBI), and one radiation dose (LD70/30 = 9.25 Gy). CD2F1 male mice were weighed, animals outside ± 10% of the mean weight were excluded, and animals were randomized into groups of four animals per box. There were 24 animals per treatment group (six boxes) for BBT-059 and its vehicle. The mice received SC administration of either BBT-059 or formulation buffer (the vehicle) at 24 h prior to TBI, 4 h post-TBI, and 24 h post-TBI. Postirradiation, the mice were monitored daily (three times a day when necessary) for 30 d, and surviving animals were euthanized at the completion of the observational period. Survival data was plotted as Kaplan-Meier plots and statistical significance of the survival differences was determined by log-rank test using GraphPad Prism 7 software (GraphPad Software, 7825 Fay Av., Suite 230, La Jolla, CA 92037 USA). For BBT-059 dose-response survival studies, each group of mice (n = 24) was administered a different dose of BBT-059 ranging from 0.01 to 1.2 mg kg −1 at either 24 h prior or 24 h post-TBI.
Hematology
To study hematological recovery in CD2F1 male mice, BBT-059 (0.3 mg kg −1 ) or its vehicle (n = 10 per group) were administered SC 24 h prior to irradiation. All animals were identified by a tail tattoo. The experimental animals received either 0 or 7 Gy radiation (nonlethal dose) at a dose rate 0.6 Gy min −1 in the AFRRI
60
Co gamma radiation facility. Blood (20 mL) was collected from the submandibular vein from all mice in ethylenediaminetetraacetic acid (EDTA) tubes at eight time points: 2 h (represented as day 0 in the graph) and days 1, 3, 7, 10, 14, 21, and 30 postdrug administration. Complete blood counts (CBCs) and differential analyses were performed using a HESKA Element HT5 Analyzer system (Cuattro Veterinary USA, 3760 Rocky Mountain Av., Loveland, CO 80538 USA). Animals were euthanized at the end of the study.
Collection of blood and tissues for various assays
BBT-059 (0.3 mg kg −1 ) or its vehicle (n = 6 per group) were administered SC 24 h prior to irradiation. The experimental animals received either 0 or 7 Gy radiation (nonlethal dose) at a dose rate of approximately 0.6 Gy min −1 in the AFRRI 60 Co gamma radiation facility. Blood was collected from the inferior vena cava under anesthesia on days 0 (2 h post-TBI), 1, 2, 3, 7, 15, and 30 after exposure at 7 Gy or from unirradiated mice followed by euthanasia. Serum was separated and used in enzyme-linked immunosorbent assay (ELISA) as described below. Femurs, sternums, and spleens were collected and processed as described below.
Hematopoietic progenitor clonogenic assay
Clonogenicity of mouse bone marrow cells was quantified in standard semisolid cultures using 1 mL of Methocult GF+ system for mouse cells (STEMCELLTechnologies Inc., 1618 Station St., Vancouver, BC, V6A 1B6, Canada) according to the manufacturer's instructions. Briefly, colonyforming units (CFUs) were assayed in irradiated mice on days 0 (2 h post-TBI), 1, 3, 7, 15, and 30 after exposure at 7 Gy or in unirradiated mice. Cells from three femurs from different animals were pooled, washed twice with Iscove's modified Dulbecco's medium (IMDM), and seeded at 1 to 5 Â 10 4 cells per dish in 35 cm cell culture dishes (BD Biosciences, 2350 Qume Dr., San Jose, CA 95131 USA). Each sample was plated in duplicate to be scored 14 d after plating. Granulocyte-macrophage CFUs (CFU-GM), granulocyte-erythrocyte-monocyte-macrophage CFUs (CFU-GEMM), erythroid CFUs (CFU-E), and erythroid burstforming units (BFU-E) were identified and quantified following the manufacturer's instructions. Colonies were counted 14 d after plating using a Nikon TS100F microscope (Nikon Instruments Inc., 1300 Walt Whitman Rd., Melville, NY 11747 USA). Fifty or more cells were considered one colony. Data are expressed as mean ± standard error of mean (SEM). Statistical significance was determined between irradiated vehicle-treated and BBT-059-treated groups.
Sternal histopathology
Following blood collection, animals were euthanized, and the sternums were collected on days 0 (2 h post-TBI), 1, 3, 7, 15, and 30 post-TBI. The sternums were fixed in a 20:1 volume of fixative (10% buffered formalin) to tissue for at least 24 h and up to 7 d. Fixed sternums were decalcified for 3 h in 12-18% sodium EDTA (pH 7.4-7.5), and specimens were dehydrated using graded ethanol concentrations and embedded in paraffin. Longitudinal 5 mm sections were stained with regular hematoxylin and eosin (H&E) stain. A board-certified veterinary pathologist conducted blinded histopathological evaluation of these samples. The bone marrow was evaluated in situ within sternebrae and graded for total cellularity and megakaryocyte numbers averaged per 10 high-power fields (HPFs) at 40Â magnification using a BX41 Olympus microscope (Nanodyne Measurement Systems, 2010 E. Hennepin Av., Minneapolis, MN 55413 USA). grade scale used for cellularity is as follows: grade 1: < 10%; grade 2: 11-30%; grade 3: 31-60%; grade 4: 61-89%; grade 5: > 90%. Images were captured with an Olympus DP70 camera (Olympus Corp., 3500 Corporate Pkwy., Center Valley, PA 18034 USA) and imported into Adobe Photoshop, version CS5 (Adobe Systems Inc., 345 Park Av., San Jose, CA 95110 USA), for analysis.
Circulating levels of EPO, TPO, and Flt3L
Mouse thrombopoietin (TPO) Quantikine ELISA kits, mouse erythropoietin (EPO) Quantikine ELISA kits, and mouse/rat Flt3 ligand (Flt3L) Quantikine ELISA kits were purchased from R&D Systems Inc. (614 McKinley Pl. NE, Minneapolis, MN 55413 USA). The cytokine detection limits were 18 pg mL , and > 5 pg mL −1 for TPO, EPO, and Flt3L ELISAs, respectively. The quantitative levels of EPO, TPO, and Flt3L were evaluated from serum samples collected on days 0 (2 h post-TBI), 2, 3, 7, and 15 post-TBI following standard protocols from the vendor. Data represented are mean ± SEM (Semenza 2001) for n = 6 mice.
Western blot analyses
Spleens were isolated and snap frozen from all groups at different time points of radiation and were stored at −80°C. Spleens were homogenized and lysed in ice cold radioimmunoprecipitation assay (RIPA) buffer (Sc24948A, Santa Cruz Biotechnology Inc., 10410 Finnel St., Dallas, TX 75220 USA) in the presence of protease inhibitors. The homogenates were centrifuged at 12,000 g for 10 min at 4°C, and the total protein concentrations were determined using a bicinchoninic acid (BCA) protein assay. After adjusting the concentrations, Laemmli sample buffer was added to 1Â final concentration. Samples were denatured by boiling at 100°C for 5 min and were run on 4-12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels at 80 V, then transferred to polyvinylidene fluoride (PVDF) membranes by semidry transfer. Membranes were blocked with 4% bovine serum albumin (BSA) and immunoblots were developed using anti-EPO (Sc7956, Santa Cruz Biotechnology; diluted 1:1000) and hypoxia-inducible factor (HIF)-2 alpha [NB100-122, Novus Biologicals (8100 Southpark Way, A-8, Littleton, CO 80120 USA); diluted 1:500]. Beta-actin (Sc47778, Santa Cruz Biotechnology) was used as an internal control. The intensities of specific bands corresponding to the proteins of interest were measured using ImageJ software.
RESULTS
Survival of lethally irradiated mice from a single dose of BBT-059
BBT-059 was found to be safe in CD2F1 male mice when administered once at 1.2 mg kg −1 body weight. The animals showed no symptoms of toxicity and gained weight during the study in a similar manner as the naive group (data not shown). No abnormal pathology was found in any of the major organs during gross necropsy.
Survival of CD2F1 mice following TBI with 9.35 Gy at the estimated rate of 0.6 Gy min −1 and therapy with a single dose of BBT-059 at 0.3 mg kg −1 or formulation buffer was tested. When BBT-059 was administered 24 h prior to TBI (Fig. 1a) , the drug-treated group had 96% survival as compared to 29% in the vehicle-treated group. When administered 4 h post-TBI (Fig. 1b) , BBT-059-treated mice had similar percent survival as seen pre-TBI. In the case of 24 h post-TBI administration of BBT-059 (Fig. 1c) , the drug-treated group showed 75% survival whereas the vehicle-treated group had 25% survival. Log-rank test p values ranged from < 0.0001-0.0005 for the survival curves when compared to the respective vehicle-treated groups.
Drug dose-response studies
In order to determine the optimum dose of BBT-059 administered 24 h pre-TBI, a range of drug doses (0.01-1.2 mg kg −1 ) were tested in mice (n = 24) at Fig. 1 . Survival of CD2F1 mice following total-body irradiation with 9.35 Gy at an estimated rate of 0.6 Gy min −1 and administration of a single dose of BBT-059 at 0.3 mg kg −1 (solid line) or formulation buffer (10 mM sodium phosphate, 4% mannitol, 1% sucrose, pH 6.2) as vehicle (dashed line). BBT-059 was administered either 24 h prior to TBI (a), 4 h post-TBI (b), or 24 h post-TBI (c). Kaplan-Meier survival curves were plotted using GraphPad software; n = 24 mice per group and trend in survival is compared between vehicle and drug-treated groups (log-rank test p < 0.0001-0.0005).
9.75 Gy (LD90/30) (Fig. 2a) . Percent survival at the lower doses (0.01 and 0.05 mg kg ). Hence, in the succeeding study the radiation dose was increased to 10.5 Gy (LD100/30) (Fig. 2b) . At BBT-059 doses of 0.3 and 0.6 mg kg −1 , more than 90% survival was observed, whereas 46% survival was observed at 0.1 mg kg
, exhibiting a good dose response. A dose of 1.2 mg kg −1 was not as effective, resulting in 79% survival (Fig. 2b) . All animals from the saline group died by day 18, and 4% survival was seen in the vehicle (formulation buffer) group, as expected for an LD100 dose of radiation.
To determine the optimum dose of BBT-059 administered 24 h post-TBI, efficacy of four doses ranging from 0.1 to 0.8 mg kg −1 was tested. A clear dose response to percent survival relationship was achieved with 0.1 and 0.3 mg kg −1 resulting in 67% and 71% survival, respectively (Fig. 3) . Similar to data shown in Fig. 2b , higher doses of BBT-059 did not result in better survival.
The optimum single dose for BBT-059 as a prophylactic as well as a mitigator was determined to be 0.3 mg kg (Fig. 4) , as well as WBCs, MONs, and LYMs (Supplemental Digital Content, Fig. 1 , http://links.lww.com/HP/ A101), were significant. There was no significant effect of BBT-059 on unirradiated mice when compared with the vehicle-treated group except in the case of PLT counts. On days 3, 5, 14, and 21, in the unirradiated BBT-059-treated group, a significant increase (p < 0.05) in PLT counts was observed compared to the unirradiated vehicle control. NEU: On day 3 post-TBI, the NEU counts decreased sharply reaching a neutropenia nadir (~58 ± 5 cells mL , p < 0.001) (Fig. 4) . On day 7 post-TBI, the BBT-059-treated group showed significant recovery from neutropenia (430 ± 54 cells mL −1 ) as compared to the vehicle-treated group (124 ± 15 cells mL −1 ). NEU cell numbers in the irradiated vehicle-treated group stayed low until day 14 post-TBI, whereas the BBT-059-treated group almost reached the NEU cell numbers in the unirradiated control groups. By day 30 all four groups had similar NEU cell counts, as the irradiation dose was nonlethal.
PLT: A platelet nadir was reached for the irradiated vehicle-treated group on day 10 but the BBT-059-treated group had a significantly higher (p < 0.0001) cell count (602 Â 10 3 ± 45 Â 10 3 cells mL −1 ) (Fig. 4) , protecting the mice from thrombocytopenia. By day 14, there was no significant difference between the unirradiated controls (989 Â 10 3 ± 125 Â 10 3 cells mL −1
) and the irradiated BBT-059-treated group (971 Â 10 3 ± 141 Â 10 3 cells mL
−1
). By day 30, the cell numbers in both irradiated groups were similar to the unirradiated controls. This data suggested that BBT-059 protected and aided in faster recovery from radiation-induced thrombocytopenia.
WBC, MON, and LYM: The irradiated group receiving BBT-059 showed markedly higher WBC and MON counts than the irradiated vehicle-treated group on days 7, 10, and 14 post-TBI, and the differences were statistically significant (p < 0.001). These results indicated that the administration of BBT-059 improved peripheral blood WBC and MON counts in irradiated mice. There were significant (p < 0.05) increases in LYM counts as well when mice were treated with BBT-059 compared to the vehicle-treated group on days 10 and 14 post-TBI.
RBC and %HCT: Changes in the RBC count and %HCT in the different groups are shown in Fig. 4 . On day 14, the %HCT of the irradiated vehicle-treated group (19 ± 2%) was significantly lower than that of the control group (38 ± 2%) or the irradiated BBT-059-treated group . BBT-059 accelerates hematopoietic progenitor cell recovery after a nonlethal dose of radiation (7 Gy) in CD2F1 mice (n = 6 per group) when administered 24 h prior to irradiation. Clonogenic potential of bone marrow cells was assessed by a colony-forming unit (CFU) assay. CFUs were assayed on days 0 (2 h post-TBI), 1, 3, 7, 15, and 30 after exposure. Cells from three femurs were pooled and counted, and each sample was plated in duplicate to be scored 14 d after plating. Data are expressed as mean ± standard error of mean (SEM). Statistical significance was determined between irradiated vehicle-treated and BBT-059-treated groups.
(33 ± 4%) (p < 0.001). The same effect was also seen in RBC counts, suggesting recovery of peripheral hematopoietic cells with BBT-059 treatment in irradiated mice.
BBT-059 protects hematopoietic progenitor cells from radiation injury when administered 24 h pre-TBI
In addition to detrimental effects on peripheral blood cells, irradiation also negatively affects the hematopoietic progenitor cells. Clonogenic assays were carried out to evaluate the extent of damage caused by irradiation and possible recovery by BBT-059 treatment administered 24 h pre-TBI. CFU assays measured CFU-GM, CFU-GEMM, CFU-E, and BFU-E to evaluate the function of hematopoietic cells. As shown in Fig. 5 , until day 7 post-TBI at 7 Gy, no colonies were observed. On day 7, the total number of colonies found in the vehicle-treated group (5 ± 2 CFUs) was significantly lower compared to the BBT-059-treated group (44 ± 2 CFUs). Even on day 15, the difference between the vehicletreated and BBT-059-treated groups with respect to GM, GEMM, BFU-E, and CFU-E was significant (p <0.0001).
Based on the CFU counts, the BBT-059-treated group recovered from radiation damage. This result suggests that the cellular functions affected by irradiation in hematopoietic progenitor cells can be restored by BBT-059 treatment.
BBT-059 restores bone marrow cellularity when administered 24 h pre-TBI Bone marrow architecture and cellularity of mice treated 24 h pre-TBI with vehicle or BBT-059 were evaluated by the board-certified veterinary pathologist (Fig. 6) . Megakaryocytes were evaluated by averaging the number of cells per 10 (40Â) HPFs. Bone marrow cellularity was determined by evaluating the amount of adipose (fat) tissue vs. hematopoietic cells (minus mature RBCs) on one (10Â) HPF. Cellularity was assigned a grade, which correlated with a percentage range of cellularity; an average was obtained for each group. The grading scheme was grade 1: < 10%; grade 2: 11-30%; grade 3: 31-60%; grade 4: 61-89%; grade 5: > 90% cellularity (Fig. 6 graph) . Specimens irradiated at 7 Gy [vehicletreated (RV), BBT-059-treated (RD)] were compared to Fig. 6 . BBT-059 treatment promoted sternal bone marrow hematopoietic cell recovery after nonlethal dose of TBI (7 Gy) when administered 24 h prior to TBI. Representative sternal bone marrow sections are shown for unirradiated vehicle (NRV) and BBT-059 (NRD) treated mice from days 0 and 30, and from vehicle (RV) and BBT-059 (RD) treated irradiated mice from days 0 (2 h post-TBI), 1, 3, 7, 15, and 30 post-TBI. Bone marrow cellularity and megakaryocyte numbers were quantitated from histological sections from days 0, 1, 3, 7, 15, and 30. Significant increases in bone marrow cellularity and megakaryocytes were observed after 15 d post-TBI in the BBT-059-treatment group. Data represented are mean ± standard error of the mean (SEM) for n = 6 mice. Percent range of cellularity: grade 1: < 10%; grade 2: 11-30%; grade 3: 31-60%; grade 4: 61-89%; grade 5: > 90%. ***p < 0.0001. respective unirradiated controls [vehicle-treated (NRV), BBT-059-treated (NRD)]. Samples were collected on different days post-TBI. The extent of recovery from radiation damage was estimated from the H&E stained slides and quantitated as number of megakaryocytes and percent cellularity (Fig. 6) . When compared to unirradiated controls (NRV or NRD), irradiated samples show significant damage in the vehicle-treated group (Paunesku et al. 2009 ) and much less in the BBT-059-treated group on day 1. On day 3, in the irradiated specimens hardly any megakaryocytes could be seen, but by day 7, the BBT-059-treated group showed recovery. By day 15 there were significant differences in the irradiated vehicle-treated and BBT-059-treated groups with respect to number of megakaryocytes as well as percent cellularity. By day 30, even though the vehicle-treated groups recovered, they still remained lower than the BBT-059-treated group.
BBT-059 attenuates radiation-induced induction of EPO, TPO, and Flt3L when administered 24 h pre-TBI
The levels of EPO, TPO, and Flt3L were evaluated by ELISA from blood serum samples collected on days 0 (2 h post-TBI), 1, 2, 3, 7, and 15 post-TBI (Fig. 7) . Mice were treated with vehicle or BBT-059 24 h prior to TBI. Serum samples from four groups of mice were compared. Two groups of mice (n = 6 per group), administered either vehicle-formulation buffer (NRV) or BBT-059 (NRD) but not irradiated, were used as controls. The levels of cytokines or biomarker in these controls were then compared to the levels observed in 7 Gy irradiated, vehicle-treated (RV) and BBT-059-treated (RD) serum samples.
EPO: EPO levels in NRV and NRD groups were found to be 144 ± 6 pg mL −1 and 376 ± 36 pg mL −1
, respectively (Fig. 7) . The difference in the EPO levels between NRV and NRD groups is not significant (p = 0.25). A gradual increase in EPO levels was seen in the irradiated groups (RV and RD) by day 3. On day 7, in the vehicle-treated RV group EPO levels were significantly higher (1,998 ± 86 pg mL ). On day 15, EPO levels in vehicle-treated specimens (RV) were around 14-fold higher (2,734 ± 406 pg mL ), indicating protection and recovery from radiation damage as a result of BBT-059 treatment.
TPO: Basal levels of TPO in NRV and NRD controls (Fig. 7) were 3,532 ± 144 pg mL −1 and 5,238 ± 305 pg mL −1 , respectively. There was not much change in TPO levels in the early time points [days 0 (2 h post-TBI), 1-3] in irradiated groups (RVand RD) compared to unirradiated controls (NRV and NRD). On day 7, TPO levels went up in the irradiated vehicle-treated group (6,069 ± 191 pg mL
) whereas in the BBT-059-treated RD group the TPO levels were Fig. 7 . BBT-059 administration 24 h prior to TBI inhibited radiation-induced elevated synthesis of EPO, TPO, and Flt3L in mouse serum when compared to vehicle-treated animals. The levels of EPO, TPO, and Flt3L were evaluated from serum from samples collected on days 0 (2 h post-TBI), 1, 2, 3, 7, and 15 post-TBI by ELISA. Data represented are mean ± standard error of the mean (SEM) for n = 6 mice per group; *p < 0.05, **p < 0.001, ***p < 0.0001. maintained at similar levels as in the unirradiated controls (4,469 ± 118 pg mL −1 ). By day 15, significant protection (p < 0.0001) was seen in the BBT-059-treated group as TPO levels were still much higher in the vehicletreated group.
Flt3L: A radiation-induced biomarker of hematopoiesis, Flt3L levels were also tested in serum (Fig. 7) . Similar to the cytokines tested above, unirradiated vehicle-treated (NRV) and BBT-059-treated (NRD) mice were used as controls with Flt3L levels of 415 ± 22 pg mL −1 and 238 ± 7 pg mL −1 , respectively. Though there was an increase in Flt3L levels on days 1 and 3, there was no difference between RV and RD groups. On day 7, the Flt3L level in the BBT-059-treated group (2,739 ± 29 pg mL ). These results suggested that the administration of BBT-059 either protected or assisted in the recovery from damage caused by irradiation.
BBT-059 inhibits radiation-induced expression of EPO and HIF-2 alpha in spleen when administered 24 h pre-TBI EPO is the hormonal regulator for the production of red cells and provides the model for oxygen-regulated gene expression like HIF (Eckardt and Kurtz 2005) . HIF-2 alpha appears to be the transcription factor that regulates EPO synthesis in the spleen. After irradiation, the amount of HIF-2 alpha increased significantly in vehicle-treated mice after 15 d; however, there was no change in the expression in vehicle-treated and BBT-059-treated mice as compared to unirradiated controls on days 0 (2 h post-TBI) and 3. This increase in HIF-2 alpha expression was also accompanied by a significant increase in EPO after 15 d (Fig. 8) . The irradiated mice that were treated with BBT-059 had significantly lower (p < 0.05) levels of HIF-2 alpha and EPO expression as compared to the vehicle-treated group. Based on these findings, it is postulated that HIF-2 alpha and EPO expression are at high levels on day 15 postirradiation. This data shows that BBT-059 inhibited the expression of hypoxic suppression by reducing the HIF-2 alpha and EPO expression, which suggests its role in protection against radiation injury.
DISCUSSION
Development of medical countermeasures against radiation (prophylactic as well as mitigatory) continues to be a significant capability shortfall and an unmet need for military personnel as well as exposed civilians. Here, the authors present a novel countermeasure, BBT-059, which demonstrates radioprotective as well as radiomitigative efficacy in CD2F1 mice exposed to TBI. This data also indicates that the drug has shown significantly better efficacy as a prophylactic countermeasure than it does as a mitigator. Although G-CSF is approved as a radiation countermeasure for ARS by the U.S. FDA, it is effective only when given after exposure in a multiple-dose regimen, which may not be feasible for a mass casualty situation. In addition, modest effects on animal survival were observed with other cytokines (IL-1, IL-3, IL-6, IL-11, IL-12, EPO, TPO, and GM-CSF) from sublethal doses of TBI (Weiss and Landauer, 2009; Hérodin et al., 2003; MacVittie and Farese, 2002; Patchen et al., 1992; Tanikawa et al., 1990; Van der Meeren et al., 2002; Whitnall et al., 2000) . Plett et al. (2014) published work on the efficacy of various PEGylated growth factors or cytokines such as G-CSF, GM-CSF, stem cell factor (SCF), tumor necrosis factor-alpha (TNF-alpha), or interferon-gamma (INF-gamma). IL-11 in combination with SCF protected mice from TBI when administered prophylactically. Orally administered IL-11 was found to be effective in mice exposed to lethal doses of TBI (Hauer-Jensen 2014). IL-11 was given at various daily doses starting 24 h post-TBI, which continued up to 5 d (Hauer-Jensen 2014) . Survival efficacy of a single-dose (24 h post-TBI) and a three-dose regimen (given on days 1, 3, and 5 post-TBI) of BBT-059 Fig. 8. (a) Western blot analysis of EPO and HIF-2 alpha in spleens of unirradiated vehicle on day 0 (0 Gy veh), 7 Gy irradiated vehicle (7 Gy Veh) and 7 Gy BBT-059 treated (7 Gy BBT) on days 0 (2 h post-TBI), 3, and 15. (b) Quantification of samples was done after analyzing three independent experiments from different samples, and the bar graph shows the quantification of the ratio of protein of interest and its respective beta-actin control; p* denotes significance level.
was compared in C57BL/6 mice (males and females) by Plett et al. (2014) . The authors showed that the three-dose regimen of BBT-059 demonstrated better efficacy than single-dose administration (given on days 1, 3, and 5 post-TBI). Plett et al. (2014) also demonstrated the efficacy of BBT-059 in both male and female C57BL/6 mice when administered 24 h post-TBI. In this study, it was shown that the drug is effective in the CD2F1 male mouse strain, which indicates that BBT-059 is effective in multiple strains and sexes. It has also been shown that BBT-059 is effective starting from 24 h pre-radiation exposure to 24 h post-radiation exposure, which is a fairly long window for protection of military personnel (before sending them to areas resulting in probable radiation exposure from cleanup operations) as well as civilian populations exposed to radiation fallout fields.
Radiation-induced peripheral blood neutropenia and thrombocytopenia can result in infection and hemorrhagic complications that could be lethal (Singh et al. 2015) . In such cases the primary cause of lethality is sepsis which results from opportunistic infection due to declines in white blood cells, eventually developing into multiple-organ failure (Singh et al. 2015) . BBT-059, administered 24 h pre-TBI, accelerated the regeneration and repletion of peripheral blood cells, particularly WBCs, NEUs, MONs, RBCs, LYMs, and PLTs. In earlier studies reported by the authors, it has been shown that pretreatment with gammatocotrienol enhances recovery of peripheral blood cells in nonlethally irradiated mice (Ghosh et al. 2009a) . In this study, BBT-059 appears to be a promising candidate for preventing radiation-induced infections and hemorrhagic complications by significantly accelerating the recovery from neutropenia and thrombocytopenia. It is interesting to note that WBC, RBC, MON, NEU, and PLT counts were significantly higher in drug-treated animals compared to irradiated controls starting from day 4 postirradiation, which indicates that BBT-059 stimulated bone marrow to protect the hematopoietic system. Radiation-induced bone marrow aplasia is one of the major consequences of apoptosis in hematopoietic stem and progenitor cells. Histopathology of sternal bone marrow was used to evaluate the effect of radiation on overall cellularity and megakaryocyte cells over 30 d. Increased restoration of sternal bone marrow was observed in pre-TBI BBT-059-treated animals, and this recovery profile correlates with the peripheral blood recovery data. There was a significant increase in the total cellularity and megakaryocyte counts on day 15 in the drug-treated animals. Similarly, recovery of bone marrow stem and progenitor cells was accelerated when BBT-059 was given 24 h before radiation, and this is in concordance with the observations of peripheral blood cell counts as well as histopathological analysis of sternal bone marrow. The surviving progenitor cells from drug-treated animals were capable of self-renewal from day 7 onward, and there were significantly higher numbers of colonies of megakaryocyte and erythroid lineages (CFU-GEMM, BFU-E, CFU-E, and CFU-GM) on both days 7 and 15 in the drug-treated group. In contrast, the progenitor population in vehicle-treated, irradiated animals exhibited poor self-renewal capacity and a resultant lack of colony formation. These findings clearly demonstrate the protective role of BBT-059 towards hematopoietic progenitor cells (HPCs). Therefore, restoring the damaged innate immune system may be one of the mechanisms of radioprotection provided by BBT-059.
The production of hematopoietic cytokines (EPO, TPO, and Flt3L) is increased after radiation (Dainiak 2002; Ossetrova et al. 2014a ). TPO, a hematopoietic growth factor mainly produced by cells in the liver and kidney, regulates megakaryocyte and platelet production (Bartley et al. 1994; Kaushansky et al. 1994; Lok et al. 1994) . Administration of recombinant TPO to rodents, nonhuman primates, and humans increased circulating platelets significantly . As seen in Fig. 7 , BBT-059-treated unirradiated and irradiated mice show small increases in EPO and TPO levels on days 0 and 1 (but no increase in Flt3L). The increase in TPO on days 0 and 1 in unirradiated animals correlates with the increase in megakaryocytes and platelets in unirradiated BBT-059-treated mice (Fig. 6 bar graph) . The data clearly shows a gradual increase in serum TPO levels in irradiated animals, with a maximum on day 7; the increase is significantly attenuated by BBT-059 on both days 7 and 15 post-TBI. Flt3L was found to be a radiation-specific biomarker for bone marrow aplasia (Ossetrova et al. 2014a and b) .
In this study, it has also been shown that serum levels of Flt3L are increased post-TBI with time and are attenuated by BBT-059. EPO, a glycoprotein also produced by cells in the liver and kidney, regulates erythropoiesis and promotes survival by proliferation and differentiation of erythroid progenitor cells (Elliott et al. 2008; Paschos et al. 2008; Ossetrova et al. 2014) . EPO is also induced by hypoxia, and its receptor is mainly regulated under conditions of reduced oxygen saturation, which can be triggered by a reduction of the hematocrit (Rosenberger et al. 2002; Barshishat-Kupper et al. 2011) . HIF-2 alpha facilitates cellular adaptation to hypoxia by stimulating a wide spectrum of biological processes (Semenza 2001) . Irradiation can cause hypoxic suppression of certain genes which might be activating HIF-2 alpha. Under hypoxia, HIF signaling is activated (Kaelin and Ratcliffe 2008) . HIF-2 appears as the main transcriptional regulator of EPO. In this study, it was shown that circulating EPO levels are increased with time, reaching a peak on day 15 post-TBI. BBT-059 administration significantly reduced the EPO levels on both days 7 and 15 post-TBI. It was also shown that hematocrit levels decline with radiation; however, accelerated recovery from day 10 was observed in the BBT-059-treated group. Since hypoxia can be triggered by a decline in hematocrit, the protein levels of HIF-2 alpha and EPO in spleens from irradiated animals was determined by Western blot. Significantly higher levels of HIF-2 alpha and EPO protein were observed in the irradiated spleens on day 15 post-TBI. Inhibition of HIF-2 alpha and EPO increases in the BBT-059-treated group suggested the drug's ability to protect the animals from radiation-induced stress.
As seen in Fig. 4 , BBT-059 is able to increase RBC and PLT levels post-TBI without increasing serum levels or spleen levels of EPO and TPO (Fig. 8) . Thus, the mechanism involved here could be the rescue/accelerated recovery of stem and progenitor cells early on, which are then able to differentiate to form RBCs and PLTs.
CONCLUSION
In summary, this study reports a promising radiation countermeasure, which is unique in its application to preventing as well as mitigating radiation injury with a broad window for medical management. The drug protects the hematopoietic system as well as inhibits the upregulation of hematopoietic cytokines and thereby, at least in part, prevents lethal radiation injury. Finally, these data support the notion that BBT-059 should be developed further for potential use with military personnel in harm's way as well as with civilians exposed in a mass casualty scenario. The authors' future plan is to develop BBT-059 further to determine the optimum schedule of administration pre-TBI and to determine a dose reduction factor.
